The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
Someone might have posted this article link before but I have to emphasise that this is a very powerful study, should be read again to see the potential: https://www.worldallergyorganizationjournal.org/article/S1939-4551(20)30401-4/fulltext
With £13million cash, the future of at least next 3 years are secured and news for multiple programmes development will be press released in the coming months and years, just puzzled to see the constant selling below 8p, anyone's guess what amount of shares can still be offloaded below the 8p mark. Any one of those development programmes coming up positive or semi-positive news, then the share price should be rising considerably, but this is AIM you can never predict one way direction movement.
with Shares in Issue total to 2.267 billion, I guess majority of issued shares owned by Australian investors, what proportion do UK institutes and PIs own?
Agree!!! issuing more shares with exercising price in the range of 0.45 - 0.65 will depress the share price further.
Comparing to other same Market Cap biopharma companies, what is the cash burning rate of MGC. I looked through their recent financial report and couldn't figure out their cash burning rate.
Got very nice profit taking and put some into UK Biotech stocks, Sareum is one with possible great potential to fight cytokine storm - the main culprit causing serious illness and death. Sareum has the best informative Chat board with a lot of objective analysis. see the link on nature article press release: https://www.lse.co.uk/rns/SAR/nature-article-highlights-role-of-tyk2-in-covid-19-l51sat7wpageos1.html
My answer is a Big Yes. Synairgen share price from 14p reached 259p, Market Capitalisationone stage is around £518m, Evgen Market Capitalisation currently is only £13m, unbelievable value for SP increasing potential.
Shifted some profits to take a position on another 'gen' suffix AIM biotech Evgen, it has multiple indications in clinical stage including Covid-19 related 300 patients clinical trial led by Dundee university Professor. Hope this can work out well.
Synairgen is a one-pony-trick of old technology/product, Market Capitalisation: £338m; Evgen has patent in place for novel drug development of multiple indications in clinical phase 2 and preclinical studies with good data package generated for next step development. Evgen's stock held by large investors and the share price is easily controlled by these large investors not by PIs. Now the placing with a decent price of 8p done, the share price will start to reflect its true value. Hope small PIs can benefit from the riding.
Considering the value of US biotech stock appreciated so much plus FED QR, Maybe it's a good idea to attract investors across the Atlantic ocean with Sareum solid science and huge ROI potential. AIM listed ARB daily trades from 3000 to 15000.
Anyone learnt enough to compare penny-stock values between London and US market. recently did some day trading on BTCs mining shares, recently started to carry out some day trading with London AIM biotech companies such as Pyc - a small biotech with Shares in Issue 97m and Market Capitalisation only £8m, Sareum and Evgen, all penny shares with great potential.
11-Sep-18 Northland Capital Partners Buy - 113.00 Reiteration
I can see the SRA737 combo trials showed as completed but no results posted so far.
History of Changes for Study: NCT02797977
A Phase 1/2 Trial of SRA737 in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer
Latest version (submitted September 23, 2020) on ClinicalTrials.gov
Below quoted Edison Quick View on Sareum prospect:
Autoimmune contender
Sareum’s novel dual tyrosine kinase 2 (TYK2) and Janus kinase 1 (JAK1) inhibitor (SDC-1801) is a potential autoimmune therapy. TYK2 and JAK (1, 2 and 3) control cell responses to various potent messenger proteins such as interleukins. The dual kinase approach may give SDC-1801 a broad range of potential indications. The leading direct competitor is a highly specific TYK2 inhibitor, deucravacitinib, from BMS. In Q420 this met its primary endpoints in a Phase III. A second Phase III reports in Q121 and may be marketed from 2022. Pfizer has both TYK2 and TYK2/JAK1 inhibitors in Phase II but is focused on a Phase III JAK3 inhibitor for alopecia. The psoriasis market is large, as shown by Otezla (Amgen), a phosphodiesterase 4 inhibitor that gained 9M20 sales of $1.6bn after being acquired in late 2019 for $13.4bn. There are already three other JAK inhibitors approved for rheumatoid arthritis, baricitinib, tofacitinib and upadacitinib.
SDC-1801 development and newsflow
Sareum aims to file a UK clinical trial authorisation in H121. If granted, a short safety and PK study could be followed by an exploratory Phase Ib study in psoriasis. TYK2 potency is established in psoriasis and trials are faster to run. These studies could, in our view, add significant additional value and may facilitate a valuable partnering deal from H222 onwards. However, we think SDC-1801 might be better positioned in other autoimmune diseases such as inflammatory bowel disease where its dual action might offer therapeutic gains.
more machines mean more BTCs mined, great long term prospect, sliced bit profit to carry out some day trading with Pyc - a small biotech with Shares in Issue 97m and Market Capitalisation only £8m, Argo one day trading amount can buy Pyc out.